Intra-articular use of a medical device composed of hyaluronic acid and chondroitin sulfate (Structovial CS): effects on clinical, ultrasonographic and biological parameters
[en] BACKGROUND:This pilot open noncontrolled study was designed to assess the efficacy of intra articular injections of a solution combining hyaluronic acid (HA) and chondroitin sulphate (CS) in the treatment of outpatients affected by knee osteoarthrosis. Findings - Thirty patients with knee OA have been included. The primary objective was to assess clinical efficacy as measured by pain and Lequesne's index. Secondary objectives were to assess potential effect of the treatment on ultrasound parameters, safety and biomarkers of cartilage metabolism and joint inflammation. After a selection visit (V1), the study treatment was administered 3 times on a weekly basis (V2, V3, V4). Follow-up was planned 6 (V5) and 12 weeks (V6) after the first intra-articular injection. Efficacy results showed a reduction in mean pain at V3 and V6 and in functional impairment, the most marked changes being measured at the two follow-up visits (V5 and V6). Although statistical significance was not achieved due to small sample size, a clear tendency towards improvement was detectable for ultrasound assessments as well as biomarkers. Except for a mild injection site hematoma for which the drug causal relationship could not be excluded, no adverse effect of clinical relevance was recorded during the study.CONCLUSION:Although this pilot study was performed according to an open design only, the ultrasound as well as biomarkers changes strongly suggest a non-placebo effect. These preliminary results call now for a randomized controlled study to confirm the clinical relevance of the observed results. Trial registration #ISRCTN91883031
Disciplines :
Rheumatology
Author, co-author :
Henrotin, Yves ; Université de Liège - ULiège > Département des sciences de la motricité > Unité de recherche sur l'os et le cartillage (U.R.O.C.)
Intra-articular use of a medical device composed of hyaluronic acid and chondroitin sulfate (Structovial CS): effects on clinical, ultrasonographic and biological parameters
Metabolic fate of exogenous chondroitin sulfate in man. Conte A, de Bernardi M, Palmieri L, Lualdi P, Mautone G, Ronca G, Arzneimittelforschung 1991 41 768 772 1772467
Metabolic fate of partially depolymerized chondroitin sulfate administered to the rat. Conte A, Palmieri L, Segnini D, Ronca G, Drugs Exp Clin Res 1991 17 27 33 1914833
Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate. Conte A, Volpi N, Palmieri L, Bahous I, Ronca G, Arzneimittelforschung 1995 45 918 925 7575762
Metabolic fate of exogenous chondroitin sulfate in the experimental animal. Palmieri L, Conte A, Giovannini L, Lualdi P, Ronca G, Arzneimittelforschung 1990 40 319 323 2112001 (Pubitemid 20103617)
Hyaluronic acid in the treatment of osteoarthritis of the knee. Huskisson EC, Donnelly S, Rheumatology (Oxford) 1999 38 602 607 10.1093/rheumatology/38. 7.602 (Pubitemid 29507326)
Intra-articular hyaluronan injections in the treatment of osteoarthritis of the knee: a randomised, double blind, placebo controlled multicentre trial. Hyaluronan Multicentre Trial Group. Lohmander LS, Dalen N, Englund G, Hamalainen M, Jensen EM, Karlsson K, Odensten M, Ryd L, Sernbo I, Suomalainen O, Tegnander A, Ann Rheum Dis 1996 55 424 431 10.1136/ard.55.7.424 8774159 (Pubitemid 26249016)
Intra-articular sodium hyaluronate in osteoarthritis of the knee: a multicenter, double-blind study. Puhl W, Bernau A, Greiling H, Kopcke W, Pforringer W, Steck KJ, Zacher J, Scharf HP, Osteoarthr Cartil 1993 1 233 241 10.1016/S1063-4584(05)80329-2 15449510
EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, Gunther K, Hauselmann H, Herrero-Beaumont G, Kaklamanis P, Lohmander S, Leeb B, Lequesne M, Mazieres B, Martin-Mola E, Pavelka K, Pendleton A, Punzi L, Serni U, Swoboda B, Verbruggen G, Zimmerman-Gorska I, Dougados M, Ann Rheum Dis 2003 62 1145 1155 10.1136/ard.2003.011742 14644851 (Pubitemid 37500619)
Effects of hyaluronic acid on the release of cartilage matrix proteoglycan and fibronectin from the cell matrix layer of chondrocyte cultures: interactions between hyaluronic acid and chondroitin sulfate glycosaminoglycan. Kato Y, Mukudai Y, Okimura A, Shimazu A, Nakamura S, J Rheumatol Suppl 1995 43 158 159 7752124
Role of chondroitin sulfate-hyaluronan interactions in the viscoelastic properties of extracellular matrices and fluids. Nishimura M, Yan W, Mukudai Y, Nakamura S, Nakamasu K, Kawata M, Kawamoto T, Noshiro M, Hamada T, Kato Y, Biochim Biophys Acta 1998 1380 1 9 10.1016/S0304-4165(97)00119-0 9545510 (Pubitemid 28141016)
Radiological assessment of osteoarthritis. Kellgren J, Lawrence D, Ann Rheum Dis 1957 16 494 502 10.1136/ard.16.4.494 13498604
Indexes of severity for osteoarthritis of the hip and knee. Validation - value in comparison with other assessment tests. Lequesne MG, Mery C, Samson M, Gerard P, Scand J Rheumatol Suppl 1987 65 85 89 3479839
Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria. Pham T, Van Der Heijde D, Lassere M, Altman RD, Anderson JJ, Bellamy N, Hochberg M, Simon L, Strand V, Woodworth T, Dougados M, J Rheumatol 2003 30 1648 1654 12858473 (Pubitemid 36835471)
Comparison between clinical evaluation and ultrasonography in detecting hydrarthrosis of the knee. Hauzeur JP, Mathy L, De Maertelaer V, J Rheumatol 1999 26 2681 2683 10606382
Changes in biochemical markers and prediction of effectiveness of intra-articular hyaluronan in patients with knee osteoarthritis. Hasegawa M, Nakoshi Y, Tsujii M, Sudo A, Masuda H, Yoshida T, Uchida A, Osteoarthr Cartil 2008 16 526 529 10.1016/j.joca.2007.09.014 17951079 (Pubitemid 351426275)
